About EMBER THERAPEUTICS INC
Ember Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the provision of treatment for metabolic disorders and obesity diseases. Its focuses on utilizing Bone Morphogenetic Protein-7 and related family of Bone Morphogenetic Proteins, mutants, variants, novel formulations, and delivery technologies to develop regenerative medicines for disease modification of osteoarthritis. The company was founded on January 20, 1987 and is headquartered in New York, NY.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of EMBT is 0.000100 USD — it hasn't changed in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange EMBER THERAPEUTICS INC stocks are traded under the ticker EMBT.
No, EMBT doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, EMBT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade EMBER THERAPEUTICS INC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So EMBER THERAPEUTICS INC technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating EMBER THERAPEUTICS INC stock shows the sell signal. See more of EMBER THERAPEUTICS INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.